- WELL Health (TSX:WELL) subsidiary, Wisp, the United States’ largest dedicated women’s telehealth provider, launched a new weight care vertical
- Wisp now offers personalized online consultations, providing access to four weight management solutions, including GLP-1 medications, to assist women dealing with hormonal issues
- Wisp has expanded its menopause solutions to address the healthcare needs of more than 2 million women experiencing menopause each year
- WELL Health Technologies stock opened trading at C$4.52 per share
WELL Health (TSX:WELL) subsidiary, Wisp, the United States’ largest dedicated women’s telehealth provider, launched a new weight care vertical.
Wisp serves more than 1.2 million patients, and the Vancouver-based digital healthcare company explained that this expansion represents an important step forward in addressing critical health needs related to hormonal imbalances and weight management for women.
Wisp now offers personalized online consultations, providing access to four weight management solutions, including GLP-1 medications, to assist women dealing with hormonal issues such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. Wisp has also launched its first exclusive over-the-counter weight care capsules aimed at enhancing women’s metabolic health.
After an online health consultation with a licensed provider, Wisp provides GLP-1 medications and supplements either through pharmacy pickup or delivery. The program also features educational content and monthly check-ins.
Wisp has expanded its menopause solutions to address the healthcare needs of more than 2 million women experiencing menopause each year. New products include Estriol Face Cream and hormone replacement therapies such as Transdermal Estradiol Patches, Oral Micronized Progesterone Capsules, and Provera Tablets. Wisp’s weight care program includes injectable and sublingual medication, blood sugar management, calorie burners and abdominal fat reduction.
“The launch of Wisp’s weight care vertical taps into the transformative potential of GLP-1 therapies,” Hamed Shahbazi, founder and CEO of WELL, said in a news release. “These treatments are reshaping healthcare by addressing weight management while enhancing metabolic health and alleviating hormonal challenges. For women experiencing conditions like PCOS, perimenopause, and menopause, GLP-1s open doors to improved health outcomes and a better quality of life. By integrating these therapies into Wisp’s offerings, we are delivering personalized care at scale and positioning ourselves at the leading edge of women’s healthcare innovation.”
WELL Health Technologies develops tech solutions and services to ensure healthcare providers are empowered to positively impact patient outcomes. Its solutions enable more than 31,000 healthcare providers across the United States and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 148 clinics.
WELL Health Technologies stock (TSX:WELL) opened trading at C$4.52 per share and is up 19.48 per cent since the year began.
Join the discussion: Find out what everybody’s saying about this stock on the WELL Health Technologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.